6 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 9 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Terminated 2, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Melphalan Hydrochloride: new trials by email Literature Review of Melphalan Hydrochloride trials Research Report on Melphalan Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation Autologous Hematopoietic Stem Cell Transplantation, Filgrastim-sndz, Melphalan Hydrochloride - Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 62 | 2019-10-09 | 2025-05-01 |
| Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant Laboratory Biomarker Analysis, Melphalan Hydrochloride, Pharmacological Study - Hematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma | Phase 2 | Withdrawn | Ohio State University Comprehensive Cancer Center | 2018-09-01 | 2020-02-21 | |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular | Phase 3 | Recruiting | Children's Oncology Group | 750 | 2018-05-14 | 2026-08-25 |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 35 | 2017-08-09 | 2026-04-14 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant Busulfan, Cyclophosphamide, Fludarabine Phosphate - Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 38 | 2017-05-30 | 2024-01-09 |
| Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Cladribine, Cyclosporine, Cytarabine - Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2 | Phase 2 | Completed | University of Washington | 30 | 2016-09-22 | 2021-11-08 |
| Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT Hydroxyurea, Alemtuzumab, Fludarabine - Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes | Phase 2 | Recruiting | Paul Szabolcs | 100 | 2014-02-04 | 2025-12-15 |
| Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). Melphalan hydrochloride - Diffuse Intrinsic Pontine Glioma (DIPG) | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 3 | 2013-03-08 | 2019-03-28 |
| Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps Fludarabine, Thiotepa, Total Body Irradiation (TBI) - Hematologic Malignancies, Acute Leukemia | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 8 | 2011-04-01 | 2025-05-31 |
| Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma Melphalan hydrochloride - Retinoblastoma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 10 | 2011-03-01 | 2018-11-27 |
| Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies CIK cells, etoposide, bcnu - Leukemia, Multiple Myeloma | Phase 1 | Completed | Sally Arai | 22 | 2006-05-01 | 2017-01-11 |
| Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma Autologous hematopoietic cell transplant (Auto-HCT), Allogeneic hematopoietic cell transplant (Allo-HCT), Cyclophosphamide - Blood Cancer, Multiple Myeloma | Phase 2 | Completed | Wen-Kai Weng | 63 | 2000-08-01 | 2018-01-18 |
Multiple Myeloma (6) · Myelodysplastic Syndromes (4) · Hodgkin Disease (3) · Graft vs Host Disease (2) · Hematologic Neoplasms (2) · Leukemia (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Lymphoma, Non-Hodgkin (2) · Myeloproliferative Disorders (2) · Adrenoleukodystrophy (1) · Anemia, Aplastic (1) · Anemia, Diamond-Blackfan (1) · Anemia, Sickle Cell (1) · Arthritis, Juvenile (1) · Autoimmune Lymphoproliferative Syndrome (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Children's Oncology Group (1) · City of Hope Medical Center (1) · M.D. Anderson Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1) · Paul Szabolcs (1) · Roswell Park Cancer Institute (1) · Sally Arai (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Washington (1) · Wen-Kai Weng (1)
United States (12) · Canada (1) · Puerto Rico (1)
Monica Pearl, M.D. (2) · Ashley Rosko, MD (1) · Dolores Grosso, DNP, CRNP (1) · Mary-Elizabeth Percival (1) · Maureen Ross (1) · Monzr Al Malki, MD (1) · Neal Flomenberg, MD (1) · Paul Szabolcs, MD (1) · Qaiser Bashir (1) · Sally Arai (1) · Steven G DuBois (1) · Wen-Kai Weng, MD (1)
PMID 32634238, PMID 32750127, PMID 34028986, PMID 34156440, PMID 42537695
P30CA015704 (1), P30CA016058 (1), U10CA180886 (1)